Limits...
Prognostic value of VEGF in patients submitted to percutaneous coronary intervention.

Ramos C, Napoleão P, Selas M, Freixo C, Viegas Crespo AM, Mota Carmo M, Cruz Ferreira R, Pinheiro T - Dis. Markers (2014)

Bottom Line: Drug eluting stent apposition and previous medication intake produced a less steep VEGF evolution after intervention (P < 0.05).Baseline VEGF concentration <40.8 pg/mL conveyed increased risk for MACE in a 5-year follow-up.Results reflect a positive role of VEGF in recovery and support its importance in CAD prognosis.

View Article: PubMed Central - PubMed

Affiliation: Instituto de Biociências e Bioengenharia (IBB), Instituto Superior Técnico, Universidade de Lisboa, Avenida Rovisco Pais 1, 1049-001 Lisboa, Portugal ; Serviço de Cardiologia, Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, 1069-024 Lisboa, Portugal.

ABSTRACT
We examined the longitudinal changes of VEGF levels after percutaneous coronary intervention for predicting major adverse cardiac events (MACE) in coronary artery disease (CAD) patients. VEGF was measured in 94 CAD patients' serum before revascularization, 1-month and 1-year after. Independently of clinical presentation, patients had lower VEGF concentration than a cohort of healthy subjects (median, IQ: 15.9, 9.0-264 pg/mL versus 419, 212-758 pg/mL; P < 0.001) at baseline. VEGF increased to 1-month (median, IQ: 276, 167-498 pg/mL; P < 0.001) and remained steady to 1-year (median, IQ: 320, 173-497 pg/mL; P < 0.001) approaching control levels. Drug eluting stent apposition and previous medication intake produced a less steep VEGF evolution after intervention (P < 0.05). Baseline VEGF concentration <40.8 pg/mL conveyed increased risk for MACE in a 5-year follow-up. Results reflect a positive role of VEGF in recovery and support its importance in CAD prognosis.

Show MeSH

Related in: MedlinePlus

Cumulative hazard for MACE according to VEGF levels (<40.8 and ≥40.8 pg/mL).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4109329&req=5

fig2: Cumulative hazard for MACE according to VEGF levels (<40.8 and ≥40.8 pg/mL).

Mentions: The VEGF levels at admission were related to a 5-year follow-up analysis considering readmission (single end point) and MACE (composite end point). Table 3 summarizes data for patients considering end points and the respective median time of event. Nineteen patients (28%) suffered MACE, with a median time of event of 10 months (IQ: 3–16). Lower VEGF concentrations at admission were significantly associated with patients with MACE compared to patients with higher VEGF: 9.0 versus 88.6 pg/mL; P = 0.028. Consistently with these results the ROC curve analysis indicated a cut-off level of 40.8 pg/mL for maximized predictive value for MACE (area under the curve of 0.664; 79% sensitivity; 56% specificity; P = 0.037). CAD group was dichotomized according to the calculated threshold level. Patients in the lower class of VEGF concentration showed increased risk for MACE, as represented in Figure 2 (Hazard Plot). The hazard ratio determined by a Cox regression was 4.4 (95% CI, 1.4 to 13.3; P = 0.009). Patients in the lower class of VEGF also showed increased risk for the primary end point of readmission (hazard ratio of 5.2; 95% CI, 1.1 to 24.1; P = 0.033).


Prognostic value of VEGF in patients submitted to percutaneous coronary intervention.

Ramos C, Napoleão P, Selas M, Freixo C, Viegas Crespo AM, Mota Carmo M, Cruz Ferreira R, Pinheiro T - Dis. Markers (2014)

Cumulative hazard for MACE according to VEGF levels (<40.8 and ≥40.8 pg/mL).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4109329&req=5

fig2: Cumulative hazard for MACE according to VEGF levels (<40.8 and ≥40.8 pg/mL).
Mentions: The VEGF levels at admission were related to a 5-year follow-up analysis considering readmission (single end point) and MACE (composite end point). Table 3 summarizes data for patients considering end points and the respective median time of event. Nineteen patients (28%) suffered MACE, with a median time of event of 10 months (IQ: 3–16). Lower VEGF concentrations at admission were significantly associated with patients with MACE compared to patients with higher VEGF: 9.0 versus 88.6 pg/mL; P = 0.028. Consistently with these results the ROC curve analysis indicated a cut-off level of 40.8 pg/mL for maximized predictive value for MACE (area under the curve of 0.664; 79% sensitivity; 56% specificity; P = 0.037). CAD group was dichotomized according to the calculated threshold level. Patients in the lower class of VEGF concentration showed increased risk for MACE, as represented in Figure 2 (Hazard Plot). The hazard ratio determined by a Cox regression was 4.4 (95% CI, 1.4 to 13.3; P = 0.009). Patients in the lower class of VEGF also showed increased risk for the primary end point of readmission (hazard ratio of 5.2; 95% CI, 1.1 to 24.1; P = 0.033).

Bottom Line: Drug eluting stent apposition and previous medication intake produced a less steep VEGF evolution after intervention (P < 0.05).Baseline VEGF concentration <40.8 pg/mL conveyed increased risk for MACE in a 5-year follow-up.Results reflect a positive role of VEGF in recovery and support its importance in CAD prognosis.

View Article: PubMed Central - PubMed

Affiliation: Instituto de Biociências e Bioengenharia (IBB), Instituto Superior Técnico, Universidade de Lisboa, Avenida Rovisco Pais 1, 1049-001 Lisboa, Portugal ; Serviço de Cardiologia, Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, 1069-024 Lisboa, Portugal.

ABSTRACT
We examined the longitudinal changes of VEGF levels after percutaneous coronary intervention for predicting major adverse cardiac events (MACE) in coronary artery disease (CAD) patients. VEGF was measured in 94 CAD patients' serum before revascularization, 1-month and 1-year after. Independently of clinical presentation, patients had lower VEGF concentration than a cohort of healthy subjects (median, IQ: 15.9, 9.0-264 pg/mL versus 419, 212-758 pg/mL; P < 0.001) at baseline. VEGF increased to 1-month (median, IQ: 276, 167-498 pg/mL; P < 0.001) and remained steady to 1-year (median, IQ: 320, 173-497 pg/mL; P < 0.001) approaching control levels. Drug eluting stent apposition and previous medication intake produced a less steep VEGF evolution after intervention (P < 0.05). Baseline VEGF concentration <40.8 pg/mL conveyed increased risk for MACE in a 5-year follow-up. Results reflect a positive role of VEGF in recovery and support its importance in CAD prognosis.

Show MeSH
Related in: MedlinePlus